Cogstate Ltd/ AU000000CGS8 /
2024-04-26 5:37:03 PM | Chg. +0.0200 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.8700USD | +2.35% | 33,000 Turnover: 28,640 |
-Bid Size: - | -Ask Size: - | 0.8800 | 0.8600 |
GlobeNewswire
2023-10-17
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
GlobeNewswire
2022-01-10
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patien...
GlobeNewswire
2021-12-01
Clinical Trial in Dementia with Lewy Bodies Used Cogstate Digital Assessments and Data Quality Servi...
GlobeNewswire
2020-11-16
Leaders from Cogstate Join the Davos Alzheimer’s Collaborative to Accelerate Innovation and Prepared...
GlobeNewswire
2020-04-29
Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Mem...
GlobeNewswire
2020-01-27
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) P...
GlobeNewswire
2020-01-27
Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial disea...
GlobeNewswire
2019-11-19
Cogstate Expands Executive Team, Appointing Ken Billard as Chief Commercial Officer
GlobeNewswire
2018-07-13
Global Cognition & Memory Enhancement Drugs Market 2018-2022: Drivers, Trends and Opportunities
GlobeNewswire
2018-01-24
IntelGenx Initiates Phase 2A Montelukast Versafilm™ Clinical Trial in Alzheimer’s Patients
GlobeNewswire
2017-12-05
Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder...
GlobeNewswire
2017-11-04
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANA...
GlobeNewswire
2017-10-12
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate A...
GlobeNewswire
2017-01-09
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase I...
GlobeNewswire
2016-12-08
Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate ...